MEDICAL THERAPIES’ REVENUE-EARNING ANIMAL TEST VALIDATED
December 11th 2008 01:51
Monday December 8, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS UP: BENITEC UP 21%, NOVOGEN DOWN 6%
* HEALTHLINX: NEW CANCER MARKER, 2nd TEST ‘98% ACCURATE’
* GENE-MARKING OBSERVED IN BENITEC HIV RNAi TRIPLE THERAPY
* MEDICAL THERAPIES’ REVENUE-EARNING ANIMAL TEST VALIDATED
* PHOSPHAGENICS PHASE I TRIAL DELIVERS TRANSDERMAL LIDOCAINE
* ACRUX APPLIES FOR ELLAVIE’S FIRST EUROPEAN SALES
* ATCOR SIGNS $2.3m SPHYGMACOR DEALS
* $2.5m FUNDING FOR HATCHTECH PHASE II HEAD LICE TRIALS
* VIRALYTICS OFFERS 4¢ A SHARE PLAN, PLACEMENT
* EASTLAND COMPLETES AFRICAN RESTRUCTURE
* SAFETY MEDICAL REQUESTS NEW PRODUCT, FINANCE TRADING HALT
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
MEDICAL THERAPIES
Medical Therapies has completed independent validation of its veterinary cancer diagnostic test which measures blood midkine levels to detect cancer in mammals.
Medical Therapies said the test was sold in Japan for diagnosing cancer in dogs.
The company said it would seek approval for the marketing of the product in Australia and in large pet-diagnostic markets such as the US and Europe.
Medical Therapies said the diagnostic test relied on blood midkine measurements by an immunoassay, essential components of which are Medical Therapies’ proprietary anti-midkine antibodies.
The company said the test complemented its human diagnostic portfolio and ensured it had full intellectual property ownership in relation to using midkine for early cancer detection in humans and animals.
Medical Therapies said the incidence of canine cancer was very high with 25 percent of dogs affected at some stage in their life.
As with humans, successful treatment correlates well with early detection.
The company said there was no test to indicate early stage solid tumors in dogs and they often developed large growths before owners became aware of the disease.
Medical Therapies said its validated midkine diagnostic test was able to detect tumors early and would contribute to improved survival rates of animals.
Medical Therapies was untraded at 3.6 cents.
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 42 |
| Vote |
Add To: 
subscribe to this blog